 DURHAM, N.C., May 10, 2021 GLOBE NEWSWIRE -- Heat Biologics, Inc. Nasdaq: HTBX, a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced the appointment of Anthony Manning, Ph.D. as Chief Scientific Advisor. Dr. Manning will be responsible for strategic initiatives to accelerate the development of Heat Biologics product portfolio. 